GenMark Receives a Buy from J.P. Morgan

By Jason Carr

J.P. Morgan analyst Tycho Peterson reiterated a Buy rating on GenMark (NASDAQ: GNMK) yesterday and set a price target of $13. The company’s shares opened today at $11.

According to, Peterson is a 5-star analyst with an average return of 11.3% and a 60.8% success rate. Peterson covers the Healthcare sector, focusing on stocks such as Dentsply International Inc., Albany Molecular Research, and Quintiles Transnational.

GenMark has an analyst consensus of Moderate Buy, with a price target consensus of $15.

The company has a one year high of $13.29 and a one year low of $4.20. Currently, GenMark has an average volume of 367.4K.

Based on the recent corporate insider activity of 85 insiders, corporate insider sentiment is negative on the stock. Most recently, in September 2016, Jon Faiz Kayyem, the SVP R&D of GNMK sold 310 shares for a total of $2,694.

GenMark Diagnostics, Inc. is a molecular diagnostics company, which is focused on developing and commercializing its proprietary eSensor detection technology. The company’s eSensor electrochemical technology enables fast, accurate and highly sensitive detection of multiple distinct biomarkers in a single sample. GenMark Diagnostics was founded by Jon Faiz Kayyem on February 12, 2010 and is headquartered in Carlsbad, CA.